Captrust Financial Advisors Nektar Therapeutics Transaction History
Captrust Financial Advisors
- $38.8 Billion
- Q1 2025
A detailed history of Captrust Financial Advisors transactions in Nektar Therapeutics stock. As of the latest transaction made, Captrust Financial Advisors holds 32,152 shares of NKTR stock, worth $22,506. This represents 0.0% of its overall portfolio holdings.
Number of Shares
32,152
Previous 12,001
167.91%
Holding current value
$22,506
Previous $11,000
90.91%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding NKTR
# of Institutions
168Shares Held
123MCall Options Held
1.18MPut Options Held
64.6K-
Black Rock Inc. New York, NY15.2MShares$10.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.3MShares$8.62 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT7.79MShares$5.45 Million0.24% of portfolio
-
Acadian Asset Management LLC Boston, MA7.3MShares$5.11 Million0.01% of portfolio
-
Eventide Asset Management, LLC Boston, MA6.65MShares$4.66 Million0.1% of portfolio
About NEKTAR THERAPEUTICS
- Ticker NKTR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,404,992
- Market Cap $131M
- Description
- Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...